Why This Matters to Distributors: McKesson is linking artificial intelligence to years of investment in distribution technology and business process automation. Rather than announcing a standalone AI product or productivity target, the pharmaceutical distributor is incorporating large language models into a broader strategy to improve efficiency, customer service, and profitability. The company has not disclosed how much of its financial improvement comes directly from AI.
Pharmaceutical distributor McKesson Corp. is adding artificial intelligence to years of investment in warehouse technology and business process automation, with CEO Brian Tyler crediting those investments as contributors to the company’s operating performance.
Tyler discussed the role of large language models and robotic process automation during McKesson’s Nov. 4 earnings call, saying the company is benefiting from technology investments made over several years.
The comments came as McKesson reported fiscal second-quarter revenue of $111 billion, up 8% from a year earlier, and net income of $1.22 billion, an increase of 10%.
Tyler said the company’s performance reflects sustained investment in its distribution network, technology, and customer relationships.
“I think the performance we’re enjoying now is an accumulation of years of focus on our strategic priorities, years of investment in technologies, whether that’s physical distribution or robotic process automation or now large language models in AI,” Tyler told analysts.
He said those investments are contributing to improvements in the company’s financial performance and its ability to serve customers.
The comments provide a clearer indication of how McKesson views AI as part of its operating strategy, although the company did not identify specific large language model applications, disclose deployment schedules or quantify the technology’s financial contribution.
McKesson’s technology strategy combines investments in physical distribution systems with software designed to automate business processes.
The company operates a large pharmaceutical distribution network serving retail pharmacies, hospitals, health systems, and specialty care providers. Its operations require extensive inventory management, order fulfillment and coordination with drug manufacturers and health care customers.
McKesson has invested in distribution infrastructure and technology to support those operations while expanding into specialty pharmaceuticals and related services.
Tyler identified robotic process automation and large language models as part of that broader investment program.
The distinction is important because the company is not presenting AI as a replacement for existing automation systems. Instead, management is describing AI as another technology contributing to improvements across the business.
McKesson has not disclosed which distribution, or administrative processes currently use large language models, how many employees use the technology or whether it has produced measurable labor savings.
The company also has not provided a separate AI investment budget.
McKesson is also expanding automated services designed to simplify the administrative work involved in obtaining prescription medications.
Its Prescription Technology Solutions business connects pharmaceutical manufacturers, pharmacies, health care providers, and insurance companies through technology that supports prescription access and affordability.
During the second quarter, McKesson added 67 programs covering 58 pharmaceutical brands, expanding services that help patients obtain prescribed medications and navigate coverage requirements.
Tyler said the company’s network now includes insurers representing 96% of U.S. prescription volume.
McKesson also introduced automated medical prior authorization capabilities, which help providers manage the insurance approval process required for certain medications and treatments.
The company is expanding those services as pharmaceutical manufacturers and health care providers seek to reduce administrative work and improve patient access to medications.
“We remain focused on leveraging technology and automation to enhance the functionality of our solutions and streamline workflows,” Tyler said.
He said the company intends to combine automated processes with specialized employees who can handle more complicated reimbursement and patient access issues.
McKesson did not specifically identify the new prior authorization capabilities or the 67 additional programs as AI applications.
The developments nevertheless illustrate the company’s broader investment in automating information-intensive services alongside its pharmaceutical distribution operations.
McKesson’s North American Pharmaceutical business reported second-quarter revenue of $91.4 billion, up 6% from a year earlier.
The increase reflected higher prescription volumes, including growth in specialty pharmaceuticals and medications used to treat diabetes and obesity.
Operating profit in the segment increased 22% to approximately $1 billion.
McKesson said the improvement reflected growth in specialty distribution and its health system business, along with continued efforts to improve operating efficiency.
The company expects further productivity gains as it invests in distribution infrastructure, technology, and supply chain operations.
Chief financial officer Kenny Cheung said McKesson plans to continue spending on automation, technology, and business growth during the second half of its fiscal year.
Those investments are included in the company’s financial outlook, which calls for continued growth in its pharmaceutical distribution and specialty health care businesses.
McKesson did not disclose how much of the segment’s profit improvement resulted from AI, robotic process automation, or other technology investments.
McKesson’s Prescription Technology Solutions business reported quarterly revenue of $1.5 billion, up 10% from a year earlier.
The increase reflected higher prescription volumes in its third-party logistics and medication access services.
Adjusted operating profit rose 18% to $307 million, driven by increased demand for services that help patients obtain medications, including prior authorization support.
The company also reported continued demand for services involving GLP-1 medications, a category that includes drugs used to treat diabetes and obesity.
McKesson said its technology and service platforms are designed to simplify administrative processes while helping pharmaceutical manufacturers, pharmacies and providers manage increasingly complex treatment and reimbursement requirements.
The growth demonstrates the expanding role of technology-enabled services in McKesson’s business, although the company did not identify AI as the specific cause of the revenue increase.
McKesson reported revenue of $110.96 billion for the fiscal second quarter ended Sept. 30, up 7.6% from $103.15 billion a year earlier.
Net income attributable to McKesson increased 9.7% to $1.22 billion from $1.11 billion.
For the first six months of fiscal 2027, revenue increased 7.6% to $216.34 billion from $200.98 billion. Net income declined 3.3% to $1.83 billion from $1.89 billion.
McKesson’s Oncology & Multispecialty business reported quarterly revenue of $15 billion, up 24%, driven by increased specialty pharmaceutical distribution and higher activity across its health care provider network.
Medical-Surgical Solutions revenue increased 5% to $3.1 billion.
The company raised its full-year adjusted earnings forecast to $45.60 to $46.40 per share, up from its previous forecast of $44.20 to $45.
The financial results reflect growth in pharmaceutical distribution, specialty medicines, and health care services. McKesson did not attribute a specific portion of that growth to AI.
McKesson expects to continue investing in automation and technology during the second half of fiscal 2027 as it expands its pharmaceutical distribution and specialty health care operations.
The company’s strategy includes improving distribution efficiency while developing services that simplify prescription access and other administrative processes.
For distributors, McKesson’s approach offers a different example of AI adoption from companies announcing individual AI products or specific productivity targets.
Tyler is connecting large language models with established investments in physical distribution and robotic process automation, rather than presenting AI as a separate technology initiative.
The company has not disclosed the financial return from its AI investments or identified specific productivity gains attributable to large language models.
Those measurements will be important in determining how much AI contributes to McKesson’s future operating performance.
Do not miss any content from Distribution Strategy Group. Join our list.
Share this article:
